Androgen receptor signaling inhibitors (ARSIs) are mainstay treatments for metastatic prostate cancer. Hyperglycemia is a common side effect, but limited data exist on outcomes such as acute care use ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

Purpose Androgen receptor signaling inhibitors (ARSIs) are mainstay treatments for metastatic prostate cancer. Hyperglycemia is a common side effect, but limited data exist on outcomes such as acute ...

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored ...

The combination of cabozantinib and atezolizumab appeared more effective than switching ARPI therapy in patients with mCRPC and extrapelvic soft-tissue metastases.

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic ...

A new single-cell endometrium atlas shows how PCOS alters endometrial cell composition, disrupts hormone signaling, and ...

Increased mitogen-activated protein kinase signaling, mediated by oncogenes such as ERBB2 or HRAS, can cause ligand-independent activation of the androgen receptor. [10, 11] The kinases and ...

DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...

An announcement from RedHill Biopharma ( ($RDHL) ) is now available. On July 1, 2025, RedHill Biopharma announced the initiation of patient ...